AstraZeneca (LON:AZN) is considering tabling a last-minute bid for $10 billion (£7.7 billion) US oncology specialist Medivation, The Sunday Times has reported. The US group, which sells a blockbuster treatment for prostate cancer, is reportedly courting bidders.
AstraZeneca’s share price has headed south this morning, having lost 1.06 percent to 4,525.50p as of 08:47 BST. The shares are underperforming the broader London market, with the benchmark FTSE 100 index having climbed marginally into positive territory and currently standing 0.20 percent
